Results 21 to 30 of about 871,767 (407)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

Cancers, 2021
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine kinase oncoprotein BCR-ABL1.
R. Alves, A. Gonçalves, S. Rutella, A. Almeida, J De Las Rivas, I. Trougakos, A. B. Sarmento Ribeiro   +6 more
semanticscholar   +1 more source

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Zita Goliasova, Petr Michalek, Petr Michalek, Veronika Smidova, Zbynek Heger, Zbynek Heger, Vojtech Adam, Vojtech Adam, Petr Hodek, Tomas Eckschlager   +9 more
openaire   +4 more sources

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells [PDF]

, 2015
Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, differentiation, cell migration and cell survival ...
Cardinali, Beatrice, FUSTAINO, VALENTINA, GIANNINI, Giuseppe, LALLI, CRISTIANA, Papoff, Giuliana, PRESUTTI, DARIO, Ruberti, Giovina, Samperna, Simone, Santini, Simonetta   +8 more
core   +9 more sources

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +4 more sources

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Journal of Hematology & Oncology, 2020
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then ...
Liling Huang, Shiyu Jiang, Yuankai Shi
semanticscholar   +1 more source

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Cancers, 2020
Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types ...
C. Pottier, Margaux Fresnais, Marie Gilon, G. Jerusalem, Rémi Longuespée, N. Sounni   +5 more
semanticscholar   +1 more source

Managing toxicities of Bruton tyrosine kinase inhibitors.

Hematology. American Society of Hematology. Education Program, 2020
Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell ...
A. Lipsky, N. Lamanna
semanticscholar   +1 more source